{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:16:36Z","timestamp":1778818596853,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences and Peking Union Medical College","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","award":["2024-I2M-C"],"award-info":[{"award-number":["2024-I2M-C"]}],"id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","award":["T-B-011"],"award-info":[{"award-number":["T-B-011"]}],"id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.eprac.2026.01.002","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:15:59Z","timestamp":1768436159000},"page":"636-643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Syndrome of Inappropriate Antidiuresis: A Systematic Review"],"prefix":"10.1016","volume":"32","author":[{"given":"Qingyi","family":"Zuo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lize","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2413-0646","authenticated-orcid":false,"given":"Hui","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.eprac.2026.01.002_bib1","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1210\/endrev\/bnad010","article-title":"Syndrome of inappropriate antidiuresis: from pathophysiology to management","volume":"44","author":"Warren","year":"2023","journal-title":"Endocr Rev"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.002_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2015.11.005","article-title":"Diagnosing and treating the syndrome of inappropriate antidiuretic hormone secretion","volume":"129","author":"Verbalis","year":"2016","journal-title":"Am J Med"},{"issue":"10 suppl 1","key":"10.1016\/j.eprac.2026.01.002_bib3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.amjmed.2013.07.006","article-title":"Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations","volume":"126","author":"Verbalis","year":"2013","journal-title":"Am J Med"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.002_bib4","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa619","article-title":"Fluid restriction therapy for chronic SIAD; results of a prospective randomized controlled trial","volume":"105","author":"Garrahy","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.002_bib5","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1530\/EJE-10-1078","article-title":"Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion","volume":"164","author":"Verbalis","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"10.1016\/j.eprac.2026.01.002_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.40313","article-title":"Use of urea for the syndrome of inappropriate secretion of antidiuretic hormone: a systematic review","volume":"6","author":"Wendt","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"21","key":"10.1016\/j.eprac.2026.01.002_bib7","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMra2115011","article-title":"Gliflozins in the management of cardiovascular disease","volume":"386","author":"Braunwald","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.002_bib8","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.002_bib9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/ndt\/gfy407","article-title":"SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA","volume":"34","author":"Sarafidis","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.eprac.2026.01.002_bib10","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/7815690","article-title":"Empagliflozin increases short-term urinary volume output in artificially induced syndrome of inappropriate antidiuresis","volume":"2017","author":"Refardt","year":"2017","journal-title":"Int J Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.002_bib11","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1681\/ASN.2019090944","article-title":"A randomized trial of empagliflozin to increase plasma sodium levels in patients with the syndrome of inappropriate antidiuresis","volume":"31","author":"Refardt","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.002_bib12","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1681\/ASN.2022050623","article-title":"Treatment effect of the SGLT2 inhibitor empagliflozin on chronic syndrome of inappropriate antidiuresis: results of a randomized, double-blind, placebo-controlled, crossover trial","volume":"34","author":"Refardt","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.eprac.2026.01.002_bib13","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.002_bib14","article-title":"Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes","volume":"5","author":"Natale","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.002_bib15","article-title":"Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus","volume":"4","author":"Hemmingsen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eprac.2026.01.002_bib16","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"suppl 1","key":"10.1016\/j.eprac.2026.01.002_bib17","doi-asserted-by":"crossref","first-page":"A619","DOI":"10.1210\/jendso\/bvab048.1263","article-title":"What does SGLT2 inhibition add in managing hyponatremia secondary to syndrome of inappropriate antidiuresis (SIAD)?","volume":"5","author":"Jalal","year":"2021","journal-title":"J Endocr Soc"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.002_bib18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s42000-023-00430-0","article-title":"Long-term efficacy of empagliflozin as an add-on treatment for chronic SIAD: a case report and literature review","volume":"22","author":"Bioletto","year":"2023","journal-title":"Hormones (Athens)"},{"key":"10.1016\/j.eprac.2026.01.002_bib19","article-title":"A case of hyponatremia precipitated by discontinuing of empagliflozin. Conference abstract","volume":"207","author":"Mirza","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.002_bib20","article-title":"Dapagliflozin for treatment of SIADH-induced hyponatraemia in an older patient with T2DM","volume":"24","author":"Muhamad","year":"2024","journal-title":"Br J Diabetes"},{"issue":"9","key":"10.1016\/j.eprac.2026.01.002_bib21","article-title":"Extraventricular neurocytoma of the sellar region presenting with syndrome of inappropriate antidiuresis","volume":"2","author":"Lamback","year":"2024","journal-title":"JCEM Case Rep"},{"key":"10.1016\/j.eprac.2026.01.002_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1453159","article-title":"Empagliflozin: a wonder drug for the treatment of SIAD?","volume":"15","author":"Tzoulis","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.002_bib23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41581-022-00673-x","article-title":"Efficacy of empagliflozin for syndrome of inappropriate antidiuresis","volume":"19","author":"Carney","year":"2023","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.002_bib24","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad011","article-title":"Prevalence of admission hyponatremia in patients with diabetes treated with and without an SGLT2 inhibitor","volume":"7","author":"Monnerat","year":"2023","journal-title":"J Endocr Soc"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.002_bib25","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/1354750X.2021.1970808","article-title":"Can treatment response to SGLT2-inhibitors in syndrome of inappropriate antidiuresis be predicted by copeptin, natriuretic peptides and inflammatory markers?","volume":"26","author":"Nobbenhuis","year":"2021","journal-title":"Biomarkers"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.002_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-21-0604","article-title":"Effect of hyponatremia normalization on osteoblast function in patients with SIAD","volume":"186","author":"Potasso","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"suppl 1","key":"10.1016\/j.eprac.2026.01.002_bib27","doi-asserted-by":"crossref","first-page":"A527","DOI":"10.1210\/jendso\/bvac150.1097","article-title":"OR27-6 Effects of the SGLT2-inhibitor empagliflozin in patients with chronic syndrome of inadequate antidiuresis (SIAD)\u2014results of a double-blind, randomized, placebo-controlled, crossover trial","volume":"6","author":"Berres","year":"2022","journal-title":"J Endocr Soc"},{"issue":"10","key":"10.1016\/j.eprac.2026.01.002_bib28","doi-asserted-by":"crossref","first-page":"e1027","DOI":"10.1210\/clinem\/dgad238","article-title":"An increase in plasma sodium levels is associated with an increase in osteoblast function in chronic SIAD","volume":"108","author":"Monnerat","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"suppl 1","key":"10.1016\/j.eprac.2026.01.002_bib29","first-page":"A729","article-title":"OR2805 Plasma sodium increase is associated with an increase in bone formation in outpatients with chronic SIAD\u2014a predefined secondary analysis of the SANDx Trial","volume":"7","author":"Monnerat","year":"2023","journal-title":"J Endocr Soc"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.002_bib30","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae106","article-title":"Apelin and copeptin levels in patients with chronic SIAD treated with empagliflozin","volume":"8","author":"Monnerat","year":"2024","journal-title":"J Endocr Soc"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.002_bib31","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-13-1020","article-title":"Clinical practice guideline on diagnosis and treatment of hyponatraemia","volume":"170","author":"Spasovski","year":"2014","journal-title":"Eur J Endocrinol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26000030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26000030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:58:27Z","timestamp":1778817507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26000030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1530891X26000030"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.01.002","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Syndrome of Inappropriate Antidiuresis: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}